Ani Pharmaceuticals (ANIP) Other financing activities (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Other financing activities data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities fell 13.1% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $13.3 million (up 106.38% YoY), and the FY2025 full-year result was $13.6 million, up 109.68% from the prior year.
• Other financing activities advanced to $2.2 million in Q1 2026, from $38000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $9.8 million in Q3 2025 to a low of $3000.0 in Q1 2022.
• A 5-year average of $1.9 million and a median of $1.2 million in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities soared 5133.33% in 2023 and tumbled 97.76% in 2025, its largest moves.
• Tracing ANIP's Other financing activities over 5 years: stood at $768000.0 in 2022, then jumped by 156.38% to $2.0 million in 2023, then declined by 13.66% to $1.7 million in 2024, then plunged by 97.76% to $38000.0 in 2025, then surged by 5694.74% to $2.2 million in 2026.
• Business Quant data shows ANIP's Other financing activities at $2.2 million in Q1 2026, $38000.0 in Q4 2025, and $9.8 million in Q3 2025.